© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gynecologic Cancers
Updated Findings Show Continued Benefit of PARP in Ovarian Cancer, New Agent on the Scene in Cervical Cancer
October 20, 2020
Several late-phase results were shared during the European Society of Medical Oncology Virtual Congress in gynecologic malignancies, but the data presented generated excitement about the number of novel options for patients after initial treatment.
Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
September 21, 2020
Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.
Atezolizumab Plus Bevacizumab and Chemotherapy Misses PFS End Point in Ovarian Cancer Trial
September 21, 2020
In patients with newly diagnosed stage III/IV ovarian cancer, adding atezolizumab to a backbone combination of bevacizumab and chemotherapy did not improve progression-free survival, missing the primary end point of the phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial presented during the virtual 2020 European Society of Medical Oncology Congress.
Non-Superiority of Weekly Dose-Dense Chemotherapy Versus SOC Shown in Epithelial Ovarian Cancer
September 21, 2020
Patients with epithelial ovarian cancer treated with weekly dose-dense chemotherapy in the ICON8 clinical trial experienced similar progression-free survival and overall survival as patients treated with the standard-of-care.
Tisotumab Vedotin Shows Promise in Recurrent/Metastatic Cervical Cancer
September 21, 2020
In the phase 2 single-arm innovaTV 204 trial, treatment with tisotumab vedotin led to an objective response rate (ORR) of 24% (95% CI, 15.9%-33.3%) in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab (Avastin). The encouraging result was announced during a presentation at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress.
Patient-Reported Outcomes Analysis Shows Maintenance of QoL in Gynecologic Cancers
September 20, 2020
Patient-reported outcomes data showed the quality of life was not reduced with niraparib in patients with ovarian, primary peritoneal, or fallopian tube cancer compared with placebo.
Durable Antitumor Activity Achieved With Dostarlimab in Mismatch Repair Proficient/dMMR Endometrial Cancer
September 20, 2020
In the phase 1 GARNET trial, durable antitumor activity was observed with dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer. The disease control rate was promising and the safety profile of the agent was tolerable, according to results presented during the 2020 European Society of Medical Oncology Virtual Congress.
Activity Observed With Balstilimab With or Without Zalifrelimab for Cervical Cancer
September 19, 2020
In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status, plus a tolerable safety profile, according to data from 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.
Randall Discusses Therapies in HRD and BRCA-Mutated Ovarian Cancer
September 10, 2020
Leslie M. Randall, MD, discussed the case of a 49-year-old African American patients with BRCA-mutated ovarian cancer.
Alvarez Discusses Bevacizumab Plus Olaparib Combo in BRCA Wild-Type Ovarian Cancer
September 07, 2020
Ronald D. Alvarez, MD, MBA, weighs the pros and cons of adding bevacizumab to olaparib as treatment of a 69-year-old male patients with BRCA-mutant ovarian cancer.